key: cord-0920902-12q9jjbb authors: Erener, Suheda title: Diabetes, Infection Risk And Covid-19 date: 2020-06-23 journal: Mol Metab DOI: 10.1016/j.molmet.2020.101044 sha: d57b9302bb5d755817be5cfdfe42fbe686c9608e doc_id: 920902 cord_uid: 12q9jjbb Abstract Background Individuals with diabetes are at a greater risk of hospitalization and mortality resulting from viral, bacterial and fungal infections. The Coronavirus Disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread quickly to more than 213 countries across the world and has claimed 395,779 lives as of June 7, 2020. Notably, in several studies, diabetes is one of the most reported comorbidities in patients with severe COVID-19. Scope of Review In this review, I will summarize the clinical data on the risk for infectious diseases in individuals with diabetes, highlighting the mechanisms for altered immune regulation. A special focus will be given to coronaviruses. In the light of the new clinical data obtained from COVID-19 patients, mechanisms such as cytokine storm, pulmonary and endothelial dysfunction, hypercoagulation that may render individuals with diabetes more vulnerable to COVID-19 will be discussed in the end. Major Conclusions Epidemiological studies show that poorly controlled diabetes is a risk factor for various infectious diseases. Given the global burden of diabetes and pandemic nature of coronaviruses, understanding how diabetes affects COVID-19 severity is critical to design tailored treatments and clinical management of individuals affected by diabetes. Diabetes is a chronic disease characterized by abnormally high blood glucose levels resulting 24 from an impairment in insulin action and/or insulin secretion. More than 425 million people 25 have diabetes world-wide and projections show this number rising to 629 million by 2045 26 [1] . While type 1 diabetes (T1D) is characterized by autoimmune mediated destruction of 27 insulin producing β-cells, type 2 diabetes (T2D) results from a combination of insulin 28 resistance and β-cell insulin secretory defect, in the long-term resulting β-cell exhaustion and 29 eventually destruction [2] . Diabetes is the leading noncommunicable, chronic pandemic 30 disease worldwide and is associated with a number of complications. Over time, high blood 31 glucose can damage the body`s tiny and large blood vessels, causing an increased risk for 32 microvascular and macrovascular complications [3] . A research study with more than 1.3 33 million participants showed that 98% of adults with type 2 diabetes have at least one urinary tract and respiratory infections among others with significantly increased 48 hospitalization and mortality rates [8-11] (Figure 1 ). An earlier report by Seshasai et al. Head and neck infections (e.g. invasive external otitis), respiratory infections (e.g. Streptococcus pneumoniae, influenza, H1N1, tuberculosis), skin and soft tissue infections (e.g. foot infection, gangrene), gastrointestinal and liver infections (e.g. Helicobacter pylori, hepatitis B, hepatitis C, enteroviruses), urinary tract infections (bacteriuria, cystitis) are more frequent in individuals with diabetes. data demonstrate that poor glycemic control is powerfully associated with serious infections. 68 In these studies, authors have also compared the infection risk between individuals with T1D 69 and T2D and found that infection-related hospitalizations and deaths were higher in 70 individuals with T1D. For instance, Carey immune responses, at least based on these studies, seem to be fairly unaffected by diabetes. 138 In the next section, current evidence on altered innate-and cell-mediated adaptive immunity 139 in individuals with diabetes will be discussed in more detail (Table 2) . 140 141 International Diabetes Federation, 2017. IDF Diabetes Atlas Classification and Diagnosis of Diabetes Vascular Complications of Diabetes 535 Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes 536 mellitus Comorbidities of diabetes and hypertension: 538 mechanisms and approach to target organ protection Chronic comorbidities in children with type 1 diabetes: 542 a population-based cohort study Mortality from cerebrovascular disease in a cohort of 23 000 patients with 545 insulin-treated diabetes Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 548 Diabetes in a Large Primary Care Cohort Study Association between glycaemic control and common infections 551 in people with Type 2 diabetes: a cohort study Type 2 diabetes and pneumonia outcomes: a population-based cohort 554 study Impact of Glycemic Control on Risk of Infections in Patients With 557 Type 2 Diabetes: A Population-Based Cohort Study Diabetes mellitus, fasting glucose, and risk of cause-specific death. 560 Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General 563 Population: A Matched Cohort Study Diabetes and the 565 severity of pandemic influenza A (H1N1) infection Hospitalized patients with 2009 H1N1 influenza in the United States Common 570 infections in diabetes: pathogenesis, management and relationship to glycaemic control. 571 Fasting plasma 573 glucose is an independent predictor for severity of H1N1 pneumonia Mortality of 2009 pandemic influenza A(H1N1) in Germany Increased risk of common infections in patients with type 1 580 and type 2 diabetes mellitus Quantifying the risk of infectious diseases for people 582 with diabetes Mechanisms of diabetic complications Type 2 diabetes influences bacterial tissue compartmentalisation in human 587 obesity Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection Cytokine secretion in long-standing diabetes mellitus type 1 and 2: 593 associations with low-grade systemic inflammation Defective phagocytosis in insulin 595 controlled diabetics: evidence for a reaction between glucose and opsonising proteins Impaired leucocyte functions in diabetic patients Distinct 600 neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune 601 diabetes in adults, and type 2 diabetes Phagocytic activity 603 is impaired in type 2 diabetes mellitus and increases after metabolic improvement Impairment of 606 polymorphonuclear leukocyte function and metabolic control of diabetes Chemotaxis of polymorphonuclear leukocytes from 609 patients with rheumatoid arthritis Sustained high glucose 611 exposure sensitizes macrophage responses to cytokine stimuli but reduces their 612 phagocytic activity alpha1-Acid glycoprotein decreases neutrophil migration and increases susceptibility to 615 sepsis in diabetic mice Polymorphonuclear cell 617 derangements in type I diabetes Diabetes 619 Mellitus and Sepsis: A Challenging Association Pneumococcal 621 immunization in adult diabetics Hyporesponsiveness to intradermal administration of hepatitis B vaccine in 624 insulin dependent diabetes mellitus The 626 immune response to influenza vaccination in diabetic patients The antibody response to influenza vaccination is not impaired in type 2 630 diabetics Impaired 632 natural killer cell subset phenotypes in human obesity Relationship 634 between natural killer cell activity and glucose control in patients with type 2 diabetes 635 and prediabetes Adipose tissue macrophages: going off track during 637 obesity Phenotypic 639 switching of adipose tissue macrophages with obesity is generated by spatiotemporal 640 differences in macrophage subtypes 642 Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in 643 adipose tissue macrophages Neutrophils in type 1 diabetes Neutrophil activation detected by increased neutrophil elastase activity in type 1 648 (insulin-dependent) diabetes mellitus Reduced blood leukocyte and neutrophil numbers in the pathogenesis of 651 type 1 diabetes Reduction of circulating neutrophils precedes and accompanies type 1 diabetes Control of T cell 656 effector functions by miRNAs Activated T lymphocytes in Type 2 diabetes: 658 implications from in vitro studies Fatty Acid Metabolites Combine with Reduced 661 beta Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes C-reactive 664 protein, interleukin 6, and risk of developing type 2 diabetes mellitus 667 The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORgammat and 668 Controls Metabolic Disease Leukocyte profiles differ between type 1 and type 2 diabetes and are 671 associated with metabolic phenotypes: results from the German Diabetes Study (GDS) 674 CD8+ effector T cells contribute to macrophage recruitment and adipose tissue 675 inflammation in obesity Elevated proinflammatory cytokine production by a skewed T 678 cell compartment requires monocytes and promotes inflammation in type 2 diabetes 681 Association of NF-E2 Related Factor 2 (Nrf2) and inflammatory cytokines in recent 682 onset Type 2 CD39 expression on Treg and Th17 685 cells is associated with metabolic factors in patients with type 2 diabetes Central role of defective interleukin-2 production in the triggering of islet autoimmune 689 destruction Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells 692 from type 1 diabetic patients Coronavirus genomics and 694 bioinformatics analysis Genomic characterisation 698 and epidemiology of 2019 novel coronavirus: implications for virus origins and 699 receptor binding A 701 pneumonia outbreak associated with a new coronavirus of probable bat origin Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-708 EMC World Health Organization, 2019. Mers Situation Update World Health Organization, 2020. Coronavirus disease (COVID-19) Situation The trinity of 715 COVID-19: immunity, inflammation and intervention Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea CoV-2 in clinical samples 722 Clinical progression and viral load in a community outbreak of coronavirus-associated 723 SARS pneumonia: a prospective study Viral Load in Upper Respiratory Specimens of Infected Patients CoV-2 infected patients with persistent negative CT findings Prevalence of comorbidities in the Middle East 730 respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-731 analysis Clinical features and short-term outcomes of 144 patients with 734 SARS in the greater Toronto area Middle 736 East respiratory syndrome coronavirus: risk factors and determinants of primary, 737 household, and nosocomial transmission Risks of Death and Severe 739 Disease in Patients With Middle East Respiratory Syndrome Coronavirus Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory 743 Syndrome Clinical 745 characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review 746 and meta-analysis Clinical course and 748 outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a 749 single-centered, retrospective, observational study Plasma 751 glucose levels and diabetes are independent predictors for mortality and morbidity in 752 patients with SARS Prevalence of comorbidities in cases of Middle East 755 respiratory syndrome coronavirus: a retrospective study 757 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Prevalence and impact of 760 cardiovascular metabolic diseases on COVID-19 in China Characteristics of and Important Lessons From the 763 COVID-19) Outbreak in China: Summary of a Report of 764 72314 Cases From the Chinese Center for Disease Control and Prevention Clinical course and risk 766 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a 767 retrospective cohort study Presenting Characteristics, Comorbidities, and Outcomes 770 Among 5700 Patients Hospitalized With COVID-19 in the Association of Blood Glucose Control and 773 Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Type 2 diabetes and COVID-19 related mortality in England: a cohort study in people 778 with diabetes. pre-print NHS Egland 780 Prevalence of obesity among adult inpatients with COVID-19 in France 783 Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital 784 admission Obesity could shift severe COVID-19 786 disease to younger ages Features of 20 133 UK patients in hospital with covid-19 using the ISARIC 789 WHO Clinical Characterisation Protocol: prospective observational cohort study 792 Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome COVID-19 795 infection: the perspectives on immune responses Clinical Characteristics 797 of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in 798 Wuhan Clinical and 800 immunological features of severe and moderate coronavirus disease 2019 SARS-CoV-2: a storm is raging Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage 804 Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice Longitudinal 807 characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of 808 SARS-CoV-2 infected patients Comorbid 810 diabetes results in immune dysregulation and enhanced disease severity following 811 MERS-CoV infection Glycemic Variability in Diabetes Increases the Severity of Influenza 816 Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-817 Grade Soluble Human ACE2 Characterization of 819 ACE and ACE2 Expression within Different Organs of the NOD Mouse Coronavirus Infections and Type 2 Diabetes-Shared Pathways 822 with Therapeutic Implications Factors determining the 824 appearance of glucose in upper and lower respiratory tract secretions Glycolytic control of vacuolar-type ATPase 827 activity: a mechanism to regulate influenza viral infection Increased 829 susceptibility of diabetic mice to influenza virus infection: compromise of collectin-830 mediated host defense of the lung by glucose? Is type 2 diabetes mellitus in mechanically ventilated adult trauma 833 patients potentially related to the occurrence of ventilator-associated pneumonia Alveolar Gas Exchange and Pulmonary Functions in 836 Patients with Type II Diabetes Mellitus Aerobic exercise 838 capacity and pulmonary function in athletes with and without type 1 diabetes Alterations of lung structure in experimental 841 diabetes, and diabetes associated with hyperlipidaemia in hamsters Diabetes mellitus induces a 844 thickening of the pulmonary basal lamina Severe Acute 846 Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome Comorbidities and multi-849 organ injuries in the treatment of COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Endothelial dysfunction in diabetes: the role of reparatory mechanisms Influenza Virus and Glycemic 857 Variability in Diabetes: A Killer Combination? 859 H5N1 and 1918 pandemic influenza virus infection results in early and excessive 860 infiltration of macrophages and neutrophils in the lungs of mice Pathogenesis of 863 influenza-induced acute respiratory distress syndrome Abnormal coagulation parameters are 865 associated with poor prognosis in patients with novel coronavirus pneumonia Prevalence of venous 868 thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with 872 COVID-19 The coagulation system in host defense Diabetes mellitus: a hypercoagulable state Hypofibrinolysis in diabetes: 878 a therapeutic target for the reduction of cardiovascular risk Hyperglycemia enhances coagulation and reduces neutrophil 882 degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human 883 endotoxemia